OmniAb (OABI) Non-Current Deferred Tax Liability (2021 - 2026)
OmniAb (OABI) reported Non-Current Deferred Tax Liability of $1.2 million for Q1 2026, down 44.43% year-over-year from $2.2 million in Q1 2025, and up 56.31% on a QoQ basis from $785000.0 in Q4 2025.
OmniAb (OABI) has 6 years of Non-Current Deferred Tax Liability data on file, last reported at $1.2 million in Q1 2026.
- Quarterly Non-Current Deferred Tax Liability fell 44.43% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 44.43% YoY) and the FY2025 annual result came in at $785000.0, down 97.78% from the prior year.
- Non-Current Deferred Tax Liability grew to $1.2 million in Q1 2026 per OABI's latest filing, from $785000.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $35.4 million in Q4 2024 and bottomed at $785000.0 in Q4 2025.
- The 5-year median for Non-Current Deferred Tax Liability is $7.8 million (2024), against an average of $10.5 million.
- The widest annual swing landed in 2024, when Non-Current Deferred Tax Liability surged 211.63%; it then tumbled 97.78% in 2025.
- Tracing OABI's Non-Current Deferred Tax Liability over 5 years: stood at $21.3 million in 2022, then sank by 46.8% to $11.4 million in 2023, then surged by 211.63% to $35.4 million in 2024, then plunged by 97.78% to $785000.0 in 2025, then soared by 56.31% to $1.2 million in 2026.
- Per Business Quant, the three latest OABI Non-Current Deferred Tax Liability figures stand at $1.2 million (Q1 2026), $785000.0 (Q4 2025), and $1.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | OmniAb | 334.72 Mn | 291.75 Mn | 14.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.23 Mn |
| Mar 31, 2026 | 1.23 Mn |
| Dec 31, 2025 | 785,000.00 |
| Dec 31, 2025 | 785,000.00 |
| Sep 30, 2025 | 1.17 Mn |
| Sep 30, 2025 | 1.17 Mn |
| Jun 30, 2025 | 2.33 Mn |
| Jun 30, 2025 | 2.33 Mn |
| Mar 31, 2025 | 2.21 Mn |
| Mar 31, 2025 | 2.21 Mn |
| Dec 31, 2024 | 35.38 Mn |
| Dec 31, 2024 | 35.38 Mn |
| Sep 30, 2024 | 4.13 Mn |
| Sep 30, 2024 | 4.13 Mn |
| Jun 30, 2024 | 6.84 Mn |
| Jun 30, 2024 | 6.84 Mn |
| Mar 31, 2024 | 8.74 Mn |
| Mar 31, 2024 | 8.74 Mn |
| Dec 31, 2023 | 11.35 Mn |
| Dec 31, 2023 | 11.35 Mn |
| Sep 30, 2023 | 13.87 Mn |
| Sep 30, 2023 | 13.87 Mn |
| Jun 30, 2023 | 17.19 Mn |
| Jun 30, 2023 | 17.19 Mn |
| Mar 31, 2023 | 20.40 Mn |
| Mar 31, 2023 | 20.40 Mn |
| Dec 31, 2022 | 21.34 Mn |
| Dec 31, 2022 | 21.34 Mn |
| Dec 31, 2021 | 21.96 Mn |
| Dec 31, 2021 | 21.96 Mn |